Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

NCT04439071
View directory record Official record
Conditions
Pneumonia, COVID-19, Coronavirus
Interventions
PTC299, SOC, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Orange, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab in Head and Neck Cancer Patients

NCT03769311
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma
Interventions
Cetuximab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
View directory record Official record
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 13, 2026, 7:33 PM EDT
Not listed Phase 4 Interventional

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

NCT04457752
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
Dual Layer Amniotic Membrane (DLAM). Artacent®
Biological
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Pembroke Pines, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 13, 2026, 7:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma NSCLC
Interventions
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
15
States / cities
Anaheim, California • San Diego, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 13, 2026, 7:33 PM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Postpartum Education Via Artificial Intelligence for Recovery and Loneliness: A Randomized Controlled Trial

NCT07223736
View directory record Official record
Conditions
Pelvic Floor Disorder, Loneliness, Postpartum, Mental Health, Depression, Peritraumatic Distress, Women, Artificial Intelligence (AI), Chatbot
Interventions
Generative artificial intelligence (genAI) postpartum chatbot, Standard of Care (SOC)
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

NCT06616844
View directory record Official record
Conditions
Wound Heal, Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Fresno, California • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

ViBandz Feasibility Study

NCT07458568
View directory record Official record
Conditions
Pediatrics, Neurologic Dysfunction, Vibration Therapy
Interventions
ViBandz
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Months to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

NCT01152918
View directory record Official record
Conditions
HIV Infection
Interventions
Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
Not listed
Enrollment
18,442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

NCT06750185
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Phlebotomy - Blood sampling for GP88 at MM, SOC Tissue biopsy
Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 13, 2026, 7:33 PM EDT
Active, not recruiting Not applicable Interventional

A Behavioral mHealth Intervention for People With HIV With Anxiety and Depression

NCT07112001
View directory record Official record
Conditions
HIV, Depression, Anxiety
Interventions
PositiveLinks with Counseling, Standard of Care (SOC)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, PuraPly AM, PuraPly XT
Other · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Clevland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

NCT03414983
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 13, 2026, 7:33 PM EDT
Not yet recruiting No phase listed Observational

PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL

NCT07829445
View directory record Official record
Conditions
LBCL, Comprehensive Genomic, Precision Treatment
Interventions
Standard of Care (SOC)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 7:33 PM EDT
Terminated Phase 4 Interventional Results available

Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations

NCT02929056
View directory record Official record
Conditions
Varicose Ulcer, Venous Insufficiency
Interventions
AmnioExCel dressing and compression therapy, SOC alginate dressing and compression therapy
Biological · Procedure
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 13, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 13, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Neurostimulation After Lumbar Surgery

NCT06100172
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use, Lumbar Spine Injury
Interventions
Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN), Sham Control Device
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 13, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth

NCT01354210
View directory record Official record
Conditions
Patient Adherence, HIV
Interventions
SMS Text Message Reminder
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
16 Years to 29 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 13, 2026, 7:33 PM EDT